title: Survival and predictors of outcomes in non-HIV-infected patients with extensively drug-resistant tuberculosis.
abstract: METHODS
  A tuberculosis (TB) referral hospital in South Korea.
  
  
  OBJECTIVE
  To evaluate predictors of treatment outcomes and survival among non-human immunodeficiency virus (HIV) infected patients with extensively drug-resistant TB (XDR-TB).
  
  
  METHODS
  Patients who were diagnosed with XDR-TB at the National Masan Tuberculosis Hospital from January 2001 to December 2005 were included in this study. We conducted a retrospective review of their medical records and mortality data.
  
  
  RESULTS
  A total of 176 non-HIV-infected patients with XDR-TB were included. TB-related mortality was 48% (84/176), and the median survival time from the diagnosis date of XDR-TB was 51 months (range 0-127, 95%CI 32.53-69.47). Cure and treatment completion were classified as favourable outcome and treatment failure, death during treatment and default as poor outcome. Previous TB treatment with second-line drugs (aOR 2.76, 95%CI 1.02-7.44) and cavitary disease (aOR 3.01, 95%CI 1.12-8.08) were independent risk factors for poor outcome. Use of linezolid (aOR 0.10, 95%CI 0.01-0.69) and surgical resection (aOR 0.18, 95%CI 0.04-0.78) were associated with favourable outcome.
  
  
  CONCLUSIONS
  There was high mortality in non-HIV-infected patients with XDR-TB at a TB referral hospital in South Korea. Adjunctive surgical treatment and linezolid improved the outcome for selected patients with XDR-TB.
authors.affiliation: National Masan Tuberculosis Hospital, Masan, South Korea; and International Tuberculosis Research Center, Masan, South Korea. sooli10kr@yahoo.co.kr
authors.forename: D S
authors.initials: DS
authors.lastname: Jeon
authors.forename: D H
authors.initials: DH
authors.lastname: Kim
authors.forename: H S
authors.initials: HS
authors.lastname: Kang
authors.forename: S H
authors.initials: SH
authors.lastname: Hwang
authors.forename: J H
authors.initials: JH
authors.lastname: Min
authors.forename: J H
authors.initials: JH
authors.lastname: Kim
authors.forename: N M
authors.initials: NM
authors.lastname: Sung
authors.forename: M W
authors.initials: MW
authors.lastname: Carroll
authors.forename: S K
authors.initials: SK
authors.lastname: Park
mesh_terms: D000328:Adult; D000995:Antitubercular Agents / Q000627:therapeutic use*; D054908:Extensively Drug-Resistant Tuberculosis / Q000401:mortality* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections; D006782:Hospitals, Special / Q000706:statistics & numerical data; D006801:Humans; D007723:Korea / Q000453:epidemiology; D008297:Male; D011013:Pneumonectomy / Q000379:methods*; D012189:Retrospective Studies; D015996:Survival Rate / Q000639:trends; D016896:Treatment Outcome
chemical_list: D000995:Antitubercular Agents